Simultaneous Assessment of Clearance, Metabolism, Induction and Drug-Drug Interaction Potential using a Long-Term In Vitro Liver Model for a Novel Hepatitis B Virus Inhibitor

Nicole A. Kratochwil[*], *Miriam Triyatni, Martina B Mueller, Florian Klammers, Brian Leonard, Dan Turley, Josephine Schmaler, Aynur Ekiciler, Birgit Molitor, Isabelle Walter, Pierre-Alexis Gonsard, Charles A. Tournillac, Alexandre Durrwell, Michaela Marschmann, Russell Jones, Mohammed Ullah, Franziska Boess, Giorgio Ottaviani, Yuyan Yin, Neil J. Parrott and Stephen Fowler*

THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (JPET)

Supplemental Data.



Supplemental Figure 1. Metabolism scheme for RO6889678. Summary of RO6889678 and its metabolites following incubation in human HepatoPac®. The relative abundance (in parenthesis) of parent drug and its metabolites is expressed as % Total Drug Related Material (%TDRM), and was estimated by comparison of peak areas of MS ion intensities. This semi-quantitative approach is based on several simplified assumptions (equimolar response of different analytes, no matrix effect).